弥漫性内生型脑桥胶质瘤的疗效评估:RAPNO工作组推荐
RAPNO工作组由国际儿童与成人神经肿瘤学家、临床医生、放射科医生、放射肿瘤学家和神经外科医生组成,针对儿童及年轻成人弥漫性内生型脑桥胶质瘤的疗效评估制定共识推荐。推荐使用脑和脊柱MRI、神经系统检查及抗炎或抗血管生成药物进行疗效评估,并定义了临床影像标准。这些推荐需在前瞻性临床试验中验证。
要点
- 推荐脑和脊柱MRI联合神经系统检查用于DIPG疗效评估。
- 抗炎或抗血管生成药物使用需纳入评估考量。
- 共识推荐需在前瞻性临床试验中验证。
核心结论
- RAPNO工作组针对儿童及年轻成人DIPG制定了疗效评估共识推荐。
研究设计与样本
- 由国际儿童与成人神经肿瘤学家、临床医生、放射科医生、放射肿瘤学家和神经外科医生组成的工作组制定共识推荐。
关键数值与推荐
- 疗效评估应使用脑和脊柱MRI、神经系统检查以及抗炎或抗血管生成药物。
- 定义了临床影像标准。
临床怎么用
- 在DIPG临床试验中采用统一的MRI和神经系统检查进行客观疗效评估。
局限性
- 推荐需在前瞻性临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimising the conduct of clinical trials for diffuse intrinsic pontine glioma involves use of consistent, objective disease assessments and standardised response criteria. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. A working group was formed specifically to address response assessment in children and young adults with diffuse intrinsic pontine glioma and to develop a consensus on recommendations for response assessment. Response should be assessed using MRI of brain and spine, neurological examination, and anti-inflammatory or antiangiogenic drugs. Clinical imaging standards are defined. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.
引用
- Cooney TM, Cohen KJ, Guimaraes CV, et al. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020. PMID: 32502459. doi:10.1016/S1470-2045(20)30166-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。